• Publications
  • Influence
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab:
Single-agent blinatumomab showed antileukemia activity in high-risk patients with Ph+ ALL who had relapsed or were refractory to TKIs and intolerant or refractor to imatinib. Expand
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
After treatment with blinatumomab in a population of patients with MRd-positive B-cell precursor ALL, a majority achieved a complete MRD response, which was associated with significantly longer RFS and OS compared with MRD nonresponders. Expand
Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with
![Graphic][1] Introduction. Prognosis of patients (pts) with R/R Philadelphia chromosome-positive (Ph+) ALL is dismal despite the introduction of tyrosine kinase inhibitors (TKI) which may be usedExpand
Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
The findings indicate that this form of adoptive immunotherapy is well tolerated and induces a low incidence of GVHD, supporting further investigation as an upfront modality to enhance graft-versus-tumor responses in high-risk patient populations. Expand
Function of NKG2D in natural killer cell–mediated rejection of mouse bone marrow grafts
It is shown that repopulating bone marrow cells in certain mouse strains expressed retinoic acid early inducible 1 proteins, which are ligands for the activating NKG2D NK cell receptor, which may contribute to graft rejection in immunocompetent hosts. Expand
Biology and clinical effects of natural killer cells in allogeneic transplantation
NK cells are a heterogeneous population of lymphocytes with diverse patterns of target-cell recognition and effector function, and further clinical and functional correlations will help maximize their potential for clinical benefit. Expand
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.
Overall survival and freedom from progression at 4 years for chronic lymphocytic leukemia patients were 73% and 47%, respectively; for mantle-cell lymphoma patients, they were 69% and 53%, respectively. Expand
Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?
Data favor an MSD over a MUD in patients age ≥50 years of allogeneic hematopoietic transplantation in leukemia/lymphoma patients, and the effect of donor type on nonrelapse mortality, relapse, and overall mortality was associated with performance score. Expand
A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant.
A novel PET radiotracer, 2'-deoxy-2'-[ 18F]fluoro-9-β-D-arabinofuranosylguanine ([18F]F-AraG), targeted toward two salvage kinase pathways preferentially accumulates in activated primary T cells, showing great potential for early aGVHD diagnosis, enabling timely treatments and improved patient outcomes. Expand
The requirement for NKG2D in NK cell-mediated rejection of parental bone marrow grafts is determined by MHC class I expressed by the graft recipient.
Interactions between the inhibitory receptors on F1 NK cells and parental major histocompatibility complex class I ligands determine whether activation via NKG2D is required to achieve the threshold for rejection of parental BM grafts. Expand